other material
confidence high
sentiment positive
materiality 0.80
Edesa Biotech reports Phase 3 paridiprubart cut 28-day mortality by 27% (p<0.001); 278-patient study positive
Edesa Biotech, Inc.
- Paridiprubart reduced adjusted 28-day mortality to 24% from 33% (27% relative risk reduction; p<0.001) in full 278-patient population.
- Consistent benefit across severity groups: 35% reduction in non-IMV (n=174) and across comorbidities (sepsis, AKI, pneumonia).
- Safety profile favorable; adverse events low and similar to placebo; over 400 patients now exposed.
- Company filed provisional patent applications for paridiprubart in sepsis, acute kidney injury, and pneumonia.